Unimicron Technology (3037) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
19 Jun, 2025Executive summary
Q1 2025 consolidated sales reached NT$30,090M (NT$30.1B), up 14% year-over-year, with net income of NT$924M, down from NT$2.66B in Q1 2024.
Gross margin was 13.4%, down from 16.3% in Q1 2024; operating margin fell to 4% from 6% year-over-year.
EPS was NT$0.60, compared to NT$1.60 in Q1 2024 and NT$0.04 in Q4 2024.
The company completed a merger with Subtron Technology effective January 1, 2025, expanding its global footprint.
Financial highlights
Operating income rose 87% sequentially to NT$1,267M but fell 20% year-over-year.
EBITDA was NT$6,157M, 20% of sales, down from 29% in Q1 2024.
Cash at period end was NT$44,143M, slightly higher than Q4 2024 but down from NT$54.8B a year earlier.
Total assets increased to NT$234.8B, and liabilities to NT$133.6B, both up year-over-year.
Operating cash flow was NT$2.75B, down from NT$3.24B in Q1 2024; capital expenditures were NT$6.78B.
Outlook and guidance
Forward-looking statements highlight risks and uncertainties that may impact future performance.
Board proposed a NT$1.50 per share cash dividend for 2024, pending approval.
Plans to issue up to NT$15B in domestic unsecured bonds over two years, with NT$4.2B at 2.10% interest in April 2025.
Latest events from Unimicron Technology
- Q4 2025 delivered higher sales, margins, and net income, led by substrate and automotive growth.3037
Q4 202525 Feb 2026 - Net sales up 12% to NT$96.55B, net income down 38%, with new bonds and HK listing planned.3037
Q3 202512 Dec 2025 - Revenue up 15% but profit and margins fell sharply amid major merger and FX risks.3037
Q2 20258 Sep 2025 - Sales up 13.8% in Q3 2024, but net income and margins declined amid expansion efforts.3037
Q3 202413 Jun 2025 - Revenue rose but profit and margins fell due to higher costs and margin pressure.3037
Q2 202413 Jun 2025 - Sales up 11%, net income down 55–58%, dividend proposed, inventory risk persists.3037
Q4 20245 Jun 2025